FBX-101 and the RESKUE Trial: Exploring AAV-Based Gene Therapies for Krabbe Disease
Related Articles
May 14, 2025
Forge Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health
Fractyl Health will leverage Forge’s FUEL™ platform to manufacture AAV for Rejuva, Fractyl's pancreatic gene therapy platform for patients with obesity and...
May 6, 2025
Forge Announces Eight Presentations at ASGCT
Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge’s FUEL™ AAV...
November 13, 2024
Affinia Therapeutics and Forge Announce AAV cGMP Manufacturing Partnership
"We’re proud to support Affinia’s vision of bringing hope to patients affected by cardiomyopathy through their innovative gene...
October 2, 2024
Forge Launches the FUEL™ AAV Manufacturing Platform
FUEL™ platform can achieve a 2-6x increase in productivity compared to industry standard, and includes pEMBR 2.0™ Ad helper and modified rep/cap...